Methylphenidate transdermal system in adults with past stimulant misuse: An open-label trial

Aimee L. McRae-Clark; Kathleen T. Brady; Karen J. Hartwell; Kathleen White; Rickey E. Carter

doi:10.1177/1087054710371171

Methylphenidate transdermal system in adults with past stimulant misuse: An open-label trial

Aimee L. McRae-Clark, Kathleen T. Brady, Karen J. Hartwell, Kathleen White, Rickey E. Carter

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Objective: This 8-week, open-label trial assessed the efficacy of methylphenidate transdermal system (MTS) in 14 adult individuals diagnosed with ADHD and with a history of stimulant misuse, abuse, or dependence. Method: The primary efficacy endpoint was the Wender-Reimherr Adult ADHD Scale (WRAADS), and secondary efficacy endpoints included the Clinical Global Impression (CGI) ratings and substance abuse as quantified by urine drug screens and self-reported use. Results: Significant improvements from baseline were found on both the WRAADS and CGI measurements. No abuse of the study medication was observed. Conclusion: The findings suggested that MTS may improve ADHD symptoms in adults with a history of stimulant misuse; however, there were limitations. The study data showed the need for subsequent randomized studies that further explore findings made in this study.

Original language	English (US)
Pages (from-to)	539-544
Number of pages	6
Journal	Journal of Attention Disorders
Volume	15
Issue number	7
DOIs	https://doi.org/10.1177/1087054710371171
State	Published - Oct 2011

Keywords

attention deficit hyperactivity disorder
stimulant misuse
transdermal methylphenidate

ASJC Scopus subject areas

Developmental and Educational Psychology
Clinical Psychology

Access to Document

10.1177/1087054710371171

Cite this

@article{f8d2f367011e47f19453ad9938ec45aa,

title = "Methylphenidate transdermal system in adults with past stimulant misuse: An open-label trial",

abstract = "Objective: This 8-week, open-label trial assessed the efficacy of methylphenidate transdermal system (MTS) in 14 adult individuals diagnosed with ADHD and with a history of stimulant misuse, abuse, or dependence. Method: The primary efficacy endpoint was the Wender-Reimherr Adult ADHD Scale (WRAADS), and secondary efficacy endpoints included the Clinical Global Impression (CGI) ratings and substance abuse as quantified by urine drug screens and self-reported use. Results: Significant improvements from baseline were found on both the WRAADS and CGI measurements. No abuse of the study medication was observed. Conclusion: The findings suggested that MTS may improve ADHD symptoms in adults with a history of stimulant misuse; however, there were limitations. The study data showed the need for subsequent randomized studies that further explore findings made in this study.",

keywords = "attention deficit hyperactivity disorder, stimulant misuse, transdermal methylphenidate",

author = "McRae-Clark, {Aimee L.} and Brady, {Kathleen T.} and Hartwell, {Karen J.} and Kathleen White and Carter, {Rickey E.}",

year = "2011",

month = oct,

doi = "10.1177/1087054710371171",

language = "English (US)",

volume = "15",

pages = "539--544",

journal = "Journal of Attention Disorders",

issn = "1087-0547",

publisher = "SAGE Publications Inc.",

number = "7",

}

TY - JOUR

T1 - Methylphenidate transdermal system in adults with past stimulant misuse

T2 - An open-label trial

AU - McRae-Clark, Aimee L.

AU - Brady, Kathleen T.

AU - Hartwell, Karen J.

AU - White, Kathleen

AU - Carter, Rickey E.

PY - 2011/10

Y1 - 2011/10

N2 - Objective: This 8-week, open-label trial assessed the efficacy of methylphenidate transdermal system (MTS) in 14 adult individuals diagnosed with ADHD and with a history of stimulant misuse, abuse, or dependence. Method: The primary efficacy endpoint was the Wender-Reimherr Adult ADHD Scale (WRAADS), and secondary efficacy endpoints included the Clinical Global Impression (CGI) ratings and substance abuse as quantified by urine drug screens and self-reported use. Results: Significant improvements from baseline were found on both the WRAADS and CGI measurements. No abuse of the study medication was observed. Conclusion: The findings suggested that MTS may improve ADHD symptoms in adults with a history of stimulant misuse; however, there were limitations. The study data showed the need for subsequent randomized studies that further explore findings made in this study.

AB - Objective: This 8-week, open-label trial assessed the efficacy of methylphenidate transdermal system (MTS) in 14 adult individuals diagnosed with ADHD and with a history of stimulant misuse, abuse, or dependence. Method: The primary efficacy endpoint was the Wender-Reimherr Adult ADHD Scale (WRAADS), and secondary efficacy endpoints included the Clinical Global Impression (CGI) ratings and substance abuse as quantified by urine drug screens and self-reported use. Results: Significant improvements from baseline were found on both the WRAADS and CGI measurements. No abuse of the study medication was observed. Conclusion: The findings suggested that MTS may improve ADHD symptoms in adults with a history of stimulant misuse; however, there were limitations. The study data showed the need for subsequent randomized studies that further explore findings made in this study.

KW - attention deficit hyperactivity disorder

KW - stimulant misuse

KW - transdermal methylphenidate

UR - http://www.scopus.com/inward/record.url?scp=80052203075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052203075&partnerID=8YFLogxK

U2 - 10.1177/1087054710371171

DO - 10.1177/1087054710371171

M3 - Article

C2 - 20538968

AN - SCOPUS:80052203075

SN - 1087-0547

VL - 15

SP - 539

EP - 544

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

IS - 7

ER -

Methylphenidate transdermal system in adults with past stimulant misuse: An open-label trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this